Faulty glucose monitors linked to 7 deaths: Here's how to address potential concerns among patients
Industry Buzz
It's so important for clinicians and users to be educated about these limitations and to remember to always confirm with a finger stick if there are any concerns about accuracy or if symptoms don't match the reading on the CGM.
—David Ahn, MD
Continuous glucose monitoring (CGM) systems have become vital tools in managing both type 1 and type 2 diabetes, providing real-time data to inform treatment decisions.
Even with today’s advances in diabetes care, technology itself can introduce risk. A recent safety warning from Abbott Diabetes Care underscores how clinical decision-making may be affected by the performance of health devices—not just provider expertise.
Abbott reported that faulty CGM sensors have been linked to seven patient deaths and hundreds of serious injuries.[] Two models were found to generate falsely low glucose readings, a failure that can prompt inappropriate treatment and place patients in harm’s way.
For clinicians managing diabetes, understanding the scope and implications of this malfunction is critical to protecting patient safety and guiding informed care decisions.
Related: Is it time for a new metric for diabetes monitoring?What happened?
Abbott Diabetes Care has issued a warning regarding defects in two of its products: the FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors.
The issue stems from a single production line and affects sensors that may deliver falsely low glucose readings. Approximately 1.5 million affected devices have either expired or been used, but a significant number of faulty units are still in circulation, posing a risk to patients who rely on these monitors for accurate glucose readings.
The company has confirmed that these inaccurate readings can lead to critical treatment decisions based on false data. For example, incorrect low glucose readings could prompt excessive carbohydrate intake or result in delayed or skipped insulin doses, potentially putting patients at serious risk, including death.
To date, seven deaths have been reported, all outside the US, along with 736 severe injuries, including 57 cases in the US.[]
Implications for physicians
The safety of patients should always be the top priority for physicians. These faulty monitors present a significant challenge in the management of diabetes. Inaccurate readings, particularly those indicating low glucose, can lead to unnecessary adjustments in treatment, including overcorrection.
A particularly concerning aspect of this issue is the potential for undetected errors to persist over time. Patients may not recognize when their glucose monitor is malfunctioning, especially if they do not regularly confirm readings with alternative methods, such as finger-stick blood glucose tests.
"It's so important for clinicians and users to be educated about these limitations and to remember to always confirm with a finger stick if there are any concerns about accuracy or if symptoms don't match the reading on the CGM," said endocrinologist David Ahn, MD, in a TikTok video breaking down the FreeStyle Libre recall.
Over-reliance on CGM devices for routine decisions—such as insulin dosing or food intake—can increase the risk of dangerous miscalculations and poor clinical outcomes.
Recommended actions for physicians
Alert patients to potential risks: It is crucial for physicians to inform patients about the possibility of faulty readings, especially for those using FreeStyle Libre devices. Abbott has launched a resource at FreeStyleCheck.com to help users determine whether their sensor is impacted. Patients should be encouraged to check their devices immediately and, if necessary, discontinue use. Abbott has said it would replace faulty devices at no charge. []
Monitor for symptoms of hypoglycemia or hyperglycemia: Physicians should consider more frequent blood glucose monitoring for patients using FreeStyle Libre 3 sensors, particularly if symptoms do not align with CGM readings. Cross-checking with traditional blood glucose tests can help ensure that treatment decisions are based on accurate data.
Consider alternative monitoring options: If patients express concerns about the safety of their device, physicians should consider offering alternative glucose monitoring options.
Stay updated on Abbott’s actions: Abbott is offering free replacements for faulty sensors, but it’s important for physicians to stay informed about the company’s ongoing actions regarding the recall. Patients should be made aware that they can quickly obtain a replacement device.
Report adverse events: Physicians should report any adverse events related to faulty glucose readings, including hypoglycemic episodes, injuries, or fatalities, to the FDA’s MedWatch program. Reporting these incidents helps the agency track potential risks and assess whether further action is necessary.
While Abbott has taken steps to replace faulty sensors, these incidents highlight broader issues in the medical device industry, particularly when it comes to managing chronic conditions like diabetes.
Physicians must advocate for greater transparency, rigorous safety testing, and quicker corrective actions when safety concerns emerge.
Related: This surprising sweet treat cuts type 2 diabetes risk by 10%